Lysosomal storage diseases as differential diagnosis of hepatosplenomegaly

Best Practice and Research: Clinical Gastroenterology

Volumn 24, Issue 5, 2010, Pages 619-628

  Vom Dahl, Stephan ^a   Mengel, Eugen ^b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Acroparesthesia; Angiokeratoma; Cholestasis; Cholesterol ester storage disease; Cirrhosis; Fabry disease; Gaucher disease; Hepatocellular carcinoma; Niemann Pick disease; Renal failure; Stroke

Indexed keywords

AGALSIDASE ALFA; AGALSIDASE BETA; CHITOTRIOSIDASE; COLESTYRAMINE; ENZYME; EZETIMIBE; IMIGLUCERASE; MEVINOLIN; MIGLUSTAT;

ADD ON THERAPY; CHOLESTEROL ESTER STORAGE DISEASE; DIFFERENTIAL DIAGNOSIS; ENZYME REPLACEMENT; FABRY DISEASE; GAUCHER DISEASE; GLYCOGEN STORAGE DISEASE TYPE 2; HEART LEFT VENTRICLE HYPERTROPHY; HEPATOSPLENOMEGALY; HUMAN; HURLER SYNDROME; LYSOSOME STORAGE DISEASE; MANNOSIDOSIS; MUCOLIPIDOSIS TYPE 2; NIEMANN PICK DISEASE; NONHUMAN; PROTEIN BLOOD LEVEL; REVIEW;

EID: 77958109525     PISSN: 15216918     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpg.2010.09.001     Document Type: Article

References (44)

1. C.M. Hollak, S. van Weely, M.H.J. van Oers, and J.M.F.G. Aerts Marked elevation of plasma chitotriosidase activity: a novel hallmark of Gaucher disease J Clin Invest 93 1994 1288 1292
2. Y. Guo, W. He, A.M. Boer, R.A. Wevers, Ad Bruijn, and J.E.M. Groener Elevated plasma chitotriosidase activity in various lysosomal storage disorders Inherit Metab Dis 18 1995 717 722
3. S. vom Dahl, K. Harzer, C. Niederau, A. Rolfs, B. Albrecht, and C. Niederau Hepatosplenomegalic lipidosis: what unless Gaucher? Adult cholesteryl ester storage disease (CESD) with anemia, mesenteric lipodystrophy, increased plasma chitotriosidase activity and a homozygous lysosomal acid lipase -1 exon 8 splice junction mutation J Hepatol 31 1999 741 746
4. M. Ries, E. Schaefer, T. Luhrs, L. Mani, J. Kuhn, and M.T. Vanier Critical assessment of chitotriosidase analysis in the rational laboratory diagnosis of children with Gaucher disease and Niemann-Pick disease type A/B and C J Inherit Metab Dis 29 2006 647 652
5. A.H. Futerman, and G. van Meer The cell biology of lysosomal storage disorders Nat Rev Mol Cell Biol 5 2004 554 565
6. R.O. Brady, J.N. Kanfer, R.M. Bradley, and D. Shapiro Demonstration of a deficiency of glucocerebroside-cleaving enzyme in Gaucher's disease J Clin Invest 45 1966 1112 1115
7. M. Jmoudiak, and A.H. Futerman Gaucher disease: pathological mechanisms and modern management Br J Haematol 129 2005 178 188
8. L.W. Poll, J.A. Koch, S. vom Dahl, M. Sarbia, D. Häussinger, and U. Mödder Gaucher disease of the spleen: CT and MR findings Abdom Imaging 25 2000 286 289
9. P.B. Deegan, and T.M. Cox Clinical evaluation of biomarkers in Gaucher disease Acta Paediatr Suppl 94 2005 47 50 discussion 37-8
10. S. vom Dahl, L. Poll, M. Di Rocco, G. Ciana, C. Denes, and G. Mariani Evidence-based recommendations for the treatment and monitoring of bone disease in Gaucher patients Curr Med Res Opin 22 2006 1045 1064
11. N.J. Weinreb, P. Deegan, K.A. Kacena, P. Mistry, G.M. Pastores, and P. Velentgas Life expectancy in Gaucher disease type 1 Am J Hematol 83 2008 896 900
12. J. Schmitz, L.W. Poll, and S. vom Dahl Therapy of adult Gaucher disease Haematologica 92 2007 148 152
13. M. de Fost, C.E. Hollak, J.E. Groener, J.M. Aerts, M. Maas, and L.W. Poll Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a 2-center retrospective analysis Blood 108 2006 830 835
14. G. Grabowski, K. Kacena, C.E. Hollak, L. Zhang, J. Yee, and P.K. Mistry Dose-response relationships for enzyme replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease type 1 Genet Med 11 2009 92 100
15. C.E. Hollak, M. de Fost, L. van Dussen, S. Vom Dahl, and J.M. Aerts Enzyme therapy for the treatment of type 1 Gaucher disease: clinical outcomes and dose - response relationships Expert Opin Pharmacother 10 2009 2641 2652
16. R.J. Wenstrup, K.A. Kacena, P. Kaplan, G.M. Pastores, A. Prakash-Cheng, and A. Zimran Effect of Enzyme Replacement Therapy With Imiglucerase on BMD in Type 1 Gaucher Disease J Bone Miner Res 22 2007 119 126 (Pubitemid 46032604)
17. A. Zimran, G. Altarescu, M. Phillips, D. Attias, M. Jmoudiak, and M. Deeb Phase I/II and extension study of velaglucerase alfa (Gene-ActivatedTM human glucocerebrosidase) replacement therapy in adults with type 1 Gaucher disease: 48-month experience Blood 2010 [Epub ahead of print]
18. T. Cox, R. Lachmann, C. Hollak, J. Aerts, S. van Weely, and M. Hrebicek Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis Lancet 355 2000 1481 1485
19. D. Elstein, C. Hollak, J.M. Aerts, S. van Weely, M. Maas, and T.M. Cox Sustained therapeutic effects of oral miglustat (Zavesca, N- butyldeoxynojirimycin, OGT 918) in type I Gaucher disease J Inherit Metab Dis 27 2004 757 766
20. P. Giraldo, P. Latre, P. Alfonso, A. Acedo, D. Alonso, and A. Barez Short-term effect of miglustat in every day clinical use in treatment-naive or previously treated patients with type 1 Gaucher's disease Haematologica 91 2006 703 706
21. A. Tylki-Szymanska, A. Vellodi, A. El-Beshlawy, J.A. Cole, and E. Kolodny Neuronopathic Gaucher disease: demographic and clinical features of 131 patients enrolled in the International Collaborative Gaucher Group Neurological Outcomes Subregistry J Inherit Metab Dis 33 2010 339 346
22. R. Steet, S. Chung, W.S. Lee, C.W. Pine, H. Do, and S. Kornfeld Selective action of the iminosugar isofagomine, a pharmacological chaperone for mutant forms of acid-beta-glucosidase Biochem Pharmacol 73 2007 1376 1383
23. H.R. Sloan, and D.S. Frederickson Enzyme deficiency in cholesteryl ester storage disease J Clin Invest 51 1972 1923 1926
24. J. Goldstein, S.E. Dana, J.R. Faust, A.L. Baudet, and M.S. Brown Role of lysosomal acid lipase in the metabolism of plasma low density lipoprotein. Observations in cultured fibroblasts from a patient with cholesteryl ester storage disease J Biol Chem 250 1975 8487 8495
25. J.M. Hoeg, S.J. Demosky Jr., O.H. Pescovitz, and H.B. Brewer Cholesteryl ester storage disease and Wolman disease: phenotypic variants of lysosomal acid cholesteryl ester hydrolase deficiency Am J Hum Genet 36 1984 1190 1203
26. D. Ameis, G. Brockmann, R. Knoblich, M. Merkel, R.E. Ostlund, and J.W. Wang A 5' splice-region mutation and a dinucleotide deletion in the lysosomal acid lipase gene in two patients with cholesteryl ester storage disease J Lipid Res 36 1995 241 250
27. L. Pisciotta, R. Fresa, A. Bellocchio, E. Pino, V. Guido, and A. Cantafora Cholesteryl Ester Storage Disease (CESD) due to novel mutations in the LIPA gene Mol Genet Metab 97 2009 143 148
28. H. Du, M. Heur, D.P. Witte, D. Ameis, and G.A. Grabowski Lysosomal acid lipase deficiency: correction of lipid storage by adenovirus-mediated gene transfer in mice Hum Gene Ther 13 2002 1361 1372
29. G.T.N. Besley, D.M. Broadhead, E. Lawlor, S.R. McCann, J.D. Dempsey, and M.I. Drury Cholesterol ester storage disease in an adult presenting with sea-blue histiocytosis Clin Genet 26 1984 195 203
30. M.T. Vanier, and K. Suzuki Niemann-Pick diseases H.W. Moser, Neurodystrophies and neurolipidoses vol. 66 1996 Elsevier Amsterdam 133 162
31. M.P. Wasserstein, A. Aron, S.E. Brodie, C. Simonaro, R.J. Desnick, and M.M. McGovern Acid sphingomyelinase deficiency: prevalence and characterization of an intermediate phenotype of Niemann-Pick disease J Pediatr 149 2006 554 559
32. C.M. Simonaro, R.J. Desnick, M.M. McGovern, M.P. Wasserstein, and E.H. Schuchman The demographics and distribution of type B Niemann-Pick disease: novel mutations lead to new genotype/phenotype correlations Am J Hum Genet 71 2002 1413 1419
33. H.K. Jin, and E.H. Schuchman Ex vivo gene therapy using bone marrow-derived cells: combined effects of intracerebral and intravenous transplantation in a mouse model of Niemann-Pick disease Mol Ther 8 2003 876 885
34. S.R. Miranda, X. He, C.M. Simonaro, S. Gatt, A. Dagan, and R.J. Desnick Infusion of recombinant human acid sphingomyelinase into niemann-pick disease mice leads to visceral, but not neurological, correction of the pathophysiology Faseb J 14 2000 1988 1995
35. S.R. Miranda, S. Erlich, V.L. Friedrich Jr., S. Gatt, and E.H. Schuchman Hematopoietic stem cell gene therapy leads to marked visceral organ improvements and a delayed onset of neurological abnormalities in the acid sphingomyelinase deficient mouse model of Niemann-Pick disease Gene Ther 7 2000 1768 1776
36. T. Dierks, L. Schlotawa, M.A. Frese, K. Radhakrishnan, K. von Figura, and B. Schmidt Molecular basis of multiple sulfatase deficiency, mucolipidosis II/III and Niemann-Pick C1 disease - Lysosomal storage disorders caused by defects of non-lysosomal proteins Biochim Biophys Acta 1793 2009 710 725
37. M.C. Patterson, D. Vecchio, H. Prady, L. Abel, and J.E. Wraith Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study Lancet Neurol 6 2007 765 772
38. C.M. Eng, N. Guffon, W.R. Wilcox, D.P. Germain, P. Lee, and S. Waldek Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry's disease N Engl J Med 345 2001 9 16
39. J. Shabbeer, M. Yasuda, S.D. Benson, and R.J. Desnick Fabry disease: identification of 50 novel alpha-galactosidase A mutations causing the classic phenotype and three-dimensional structural analysis of 29 missense mutations Hum Genomics 2 2006 297 309
40. R.J. Desnick, Y.A. Ioannou, and C.M. Eng Fabry's disease? C. Scriver, A.L. Beadet, W.S. Sly, D. Valle, The metabolic and molecular basis of inherited disease 8 ed. 2001 McGraw-Hill New York 3733 3774
41. W.R. Wilcox, M. Banikazemi, N. Guffon, S. Waldek, P. Lee, and G.E. Linthorst Long-term safety and efficacy of enzyme replacement therapy for Fabry disease Am J Hum Genet 75 2004 65 74
42. D.P. Germain, S. Waldek, M. Banikazemi, D.A. Bushinsky, J. Charrow, and R.J. Desnick Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease J Am Soc Nephrol 18 2007 1547 1557
43. M. Banikazemi, J. Bultas, S. Waldek, W.R. Wilcox, C.B. Whitley, and M. McDonald Agalsidase-beta therapy for advanced Fabry disease: a randomized trial Ann Intern Med 146 2007 77 86
44. E. Lukina, N. Watman, E.A. Arreguin, M. Banikazemi, M. Dragosky, and M. Iastrebner A Phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1 Blood 2010 [Epub ahead of print]